Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
4.11
Dollar change
+0.20
Percentage change
5.12
%
Index- P/E- EPS (ttm)-2.36 Insider Own- Shs Outstand82.85M Perf Week18.10%
Market Cap340.51M Forward P/E- EPS next Y-0.77 Insider Trans- Shs Float82.85M Perf Month13.85%
Income-161.86M PEG- EPS next Q-0.45 Inst Own10.54% Short Float0.16% Perf Quarter37.46%
Sales0.12M P/S2837.61 EPS this Y51.11% Inst Trans- Short Ratio4.74 Perf Half Y141.76%
Book/sh-0.57 P/B- EPS next Y38.50% ROA-101.00% Short Interest0.14M Perf Year-10.26%
Cash/sh1.90 P/C2.17 EPS next 5Y- ROE-3388.40% 52W Range1.60 - 4.42 Perf YTD39.32%
Dividend Est.- P/FCF- EPS past 5Y-37.62% ROI-120.88% 52W High-7.01% Beta-
Dividend TTM- Quick Ratio5.10 Sales past 5Y13.73% Gross Margin- 52W Low156.88% ATR (14)0.29
Dividend Ex-Date- Current Ratio5.10 EPS Y/Y TTM-193.00% Oper. Margin-141208.56% RSI (14)73.00 Volatility8.23% 7.66%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin-138173.67% Recom2.00 Target Price10.71
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-5.23% Payout- Rel Volume0.38 Prev Close3.91
Sales Surprise143.20% EPS Surprise-36.67% Sales Q/Q17.75% EarningsFeb 28 AMC Avg Volume28.48K Price4.11
SMA2017.80% SMA5030.27% SMA20054.26% Trades Volume10,902 Change5.12%
Date Action Analyst Rating Change Price Target Change
Dec-08-22Initiated H.C. Wainwright Buy $14
Apr-26-22Initiated SVB Leerink Outperform $25
Nov-17-20Initiated Citigroup Buy $48
Nov-11-20Initiated Truist Buy $25
Nov-11-20Initiated SVB Leerink Outperform $33
Nov-11-20Initiated Oppenheimer Outperform $36
Mar-24-24 07:55AM
Mar-19-24 06:00AM
Mar-05-24 05:08PM
Feb-28-24 05:55PM
Feb-19-24 06:25PM
07:00AM Loading…
Feb-14-24 07:00AM
Feb-05-24 03:11AM
Feb-01-24 06:00AM
Dec-27-23 06:00AM
Dec-19-23 06:00AM
Dec-01-23 05:30AM
Nov-09-23 05:30AM
Oct-30-23 05:30AM
Oct-27-23 05:30AM
Oct-02-23 05:30AM
05:30AM Loading…
Sep-07-23 05:30AM
Aug-28-23 05:30AM
Jul-26-23 06:00AM
Jul-24-23 06:00AM
Jul-13-23 06:00AM
Jul-10-23 06:00AM
Jun-08-23 06:00AM
May-25-23 08:00AM
06:00AM
May-17-23 06:00AM
May-08-23 05:30AM
Apr-28-23 05:30AM
Mar-07-23 06:00AM
Mar-06-23 06:00AM
Feb-13-23 06:00AM
06:00AM Loading…
Feb-06-23 06:00AM
Jan-30-23 06:00AM
Dec-12-22 10:08AM
Dec-09-22 03:00PM
Dec-06-22 06:00AM
Nov-10-22 06:00AM
Oct-24-22 06:00AM
Sep-18-22 07:15PM
Aug-30-22 06:00AM
Aug-16-22 07:46AM
Aug-14-22 09:02PM
09:01PM
Jun-19-22 07:05PM
May-11-22 08:00AM
May-10-22 08:20AM
May-05-22 06:00AM
Apr-29-22 06:00AM
Apr-22-22 08:15AM
Apr-10-22 08:12PM
Mar-21-22 04:00AM
Mar-10-22 06:00AM
Mar-02-22 06:00AM
Feb-14-22 09:06AM
06:00AM
Feb-10-22 06:00AM
Feb-09-22 06:00AM
Jan-24-22 06:00AM
Jan-10-22 05:59PM
Jan-04-22 06:18AM
Jan-03-22 06:00AM
Oct-26-21 06:00AM
Oct-19-21 06:00AM
Oct-12-21 05:41PM
Oct-04-21 07:00AM
Sep-07-21 08:20PM
Sep-02-21 07:00AM
Aug-30-21 07:00AM
Aug-10-21 07:00AM
Aug-09-21 07:00AM
Jul-06-21 07:00AM
Jun-16-21 04:06PM
Jun-15-21 12:27PM
Jun-14-21 07:00AM
Jun-01-21 07:11AM
May-31-21 04:27PM
Apr-06-21 05:30AM
Mar-31-21 05:30AM
Mar-15-21 05:30AM
Mar-10-21 05:30AM
Mar-02-21 02:20PM
Feb-24-21 05:30AM
Feb-17-21 05:30AM
Oct-20-20 09:38PM
Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.